Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Lu AF35700 in Patients With Schizophrenia
NCT02202226Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Jan 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing Lu AF35700 with Placebo (2 arms). Primary endpoints: Absolute values and change from baseline in safety variables, Change from baseline in AIMS, BARS and SAS Total score and 1 more. Started Jan 2013; status: completed.
02
Drugs
lu af35700
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02202226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202226.